This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
by Zacks Equity Research
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
by Zacks Equity Research
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
by Zacks Equity Research
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
by Zacks Equity Research
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
by Zacks Equity Research
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
by Kinjel Shah
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
by Zacks Equity Research
AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
by Zacks Equity Research
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
by Zacks Equity Research
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
Merck (MRK) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session.
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
by Kinjel Shah
FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Merck (MRK) closed at $127.99 in the latest trading session, marking a +0.38% move from the prior day.
Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
by Zacks Equity Research
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
by Zacks Equity Research
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $130.20, denoting a -1.24% change from the preceding trading day.
Top Analyst Reports for Microsoft, Apple & Alphabet
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Apple Inc. (AAPL) and Alphabet Inc. (GOOGL), as well as a micro-cap stock CompX International Inc. (CIX).
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
by Zacks Equity Research
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
Merck (MRK) Stock Moves 0.27%: What You Should Know
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $131.84, representing a +0.27% change from its previous close.
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Merck (MRK) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $129.45, representing a +0.57% change from its previous close.
Company News for June 4, 2024
by Zacks Equity Research
Companies In The Article Are:NVDA, MRK,MRNA, SPOT, SRCL and WM
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
by Kinjel Shah
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.